Entrada Therapeutics (TRDA)
(Delayed Data from NSDQ)
$5.30 USD
-0.65 (-10.92%)
Updated Aug 7, 2025 04:00 PM ET
After-Market: $5.28 -0.02 (-0.38%) 7:14 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Entrada Therapeutics, Inc.'s return on equity, or ROE, is -17.35% compared to the ROE of the Medical - Biomedical and Genetics industry of -60.93%. While this shows that TRDA has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
TRDA 5.30 -0.65(-10.92%)
Will TRDA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TRDA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TRDA
Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Lags Revenue Estimates
Entrada Therapeutics (TRDA) Soars 5.6%: Is Further Upside Left in the Stock?
TRDA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue Estimates
Eton Pharmaceuticals, Inc. (ETON) Earnings Expected to Grow: What to Know Ahead of Q1 Release
Analysts Estimate Entrada Therapeutics, Inc. (TRDA) to Report a Decline in Earnings: What to Look Out for
Other News for TRDA
Entrada Therapeutics price target lowered by $4 at Roth Capital, here's why
Entrada Therapeutics (TRDA) Hits Key Milestone in Duchenne Therapy Trials
Entrada Therapeutics GAAP EPS of -$1.04, revenue of $2M
Entrada Therapeutics Reports Second Quarter 2025 Financial Results | TRDA Stock News
Entrada Therapeutics reports Q2 EPS ($1.04), consensus (86c)